Amgen reported a strong Q4 with significant advances in the pipeline, cost-savings, and optimistic revenue and EPS guidance for 2013. However, shares might experience only modest immediate upward movement due to uncertainties around specific product revenues, potential effects from new regulations, and a focus on long-term rather than short-term growth. 
[0]